{"entity":{"id":"nct05890742","kind":"trial","name":"A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer","aka":[],"tldr":"A phase 3 trial of Sintilimab in colorectal cancer, run by Innovent Biologics (Suzhou) Co. Ltd., active and no longer recruiting.","summary":"A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer is a phase 3 interventional study registered as NCT05890742 by Innovent Biologics (Suzhou) Co. Ltd., with 453 participants enrolled, started 2023-05-25 and due to reach its primary completion in 2028-04-15. Interventions recorded: Sintilimab, IBI310&Sintilimab and Radical surgery.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05890742","url":"https://clinicaltrials.gov/study/NCT05890742"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal","msi-high-colorectal"],"sections":[],"technologies":["checkpoint-inhibitor","monoclonal-antibody"],"targets":[],"drugs":["sintilimab"],"companies":["innovent"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct05890742-cancer-cell-2025"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05890742","phase":"3","setting":"A Phase 1b/3 Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","started":"2023-05-25","startedType":"actual","enrolled":453,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05890742/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}],"company":[{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/"}],"paper":[{"id":"paper-nct05890742-cancer-cell-2025","kind":"paper","name":"Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study","route":"/key-papers/paper-nct05890742-cancer-cell-2025/"}],"idea":[{"id":"idea-immunotherapy-mss-crc","kind":"idea","name":"Making microsatellite-stable colorectal cancer immunotherapy-responsive","route":"/ideas/idea-immunotherapy-mss-crc/"}]}}